Leo has indicated that he would like IPIX to follow the royalty model -- develop the drugs, license them out. What would you rather have, a one-time big payment, or royalties over a long period of time while some small percentage of that money goes into developing even more royalty-producing drugs? I'd rather have the royalty model, especially given the mammoth potential of Brilacidin in its many forms. (And, if Kevetrin really cures a whole bunch of cancers...... the potential is astounding)

But, I don't think anyone would be upset with a modest payment like, for instance, $100/share